Clinical trial · Interventional
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199069CI-TRIAL-00064777completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study evaluates the efficacy and tolerability of a risk- and subtype-adapted chemotherapy over one year, followed by randomized either intensified or conventional maintenance therapy. It includes a distinct protocol for the subgroup 'mature B-ALL',
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Lymphocytic Leukemia | Adult Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (15)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 6-Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| 6-Thioguanine | Drug | Thioguanine | ALIAS |
| Asparaginase | Drug | Asparaginase | ALIAS |
| CNS Irradiation | Procedure | — | UNRESOLVED |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin, Adriamycin | Drug | — | UNRESOLVED |
| Dexamethasone / Prednisolone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- remission rate, disease free survival, overall survival
Secondary outcomes (1)
- measure
- death in induction, toxicity, time and dose compliance
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Acute Lymphocytic Leukemia * Age 15 - 65 years Exclusion Criteria: * Serious secondary diseases which may compromise intensified chemotherapeutical treatment * Serious psychiatric diseases, which may compromise compliance with therapy * HIV-1 or HIV-2 Infection * Pretreatment \> 2 weeks or chemotherapy other than Vincristine and Steroids * Patients without central diagnosis who cannot be allocated to a risk group
References
Publications (0)
Data not yet available
No reference posted for this study.